Emma Stanton

Emma joins at a time when the potential clinical applications of nanopore sequencing are rapidly expanding. Her experience in medical and clinical affairs will support our ambitions for growth in healthcare applications over the coming years. Emma will work closely with the clinical market development team to accelerate the introduction and scale up of a range of clinical applications. In addition, Emma will work closely with DHSC and NHS colleagues with the goal of leveraging our LamPORE diagnostic platform for COVID 19 to add new clinical assays.

Until November this year, Emma was Director of Testing Supplies and Innovation at NHS Test and Trace. Prior to this, Emma was CEO of a health care company focussed on improving efficiency across elective care pathways in the NHS. Emma brings international healthcare experience from the US where she worked for a large payer based in Massachusetts and was previously a Commonwealth Fund Harkness Fellow in Healthcare Policy and Practice at Harvard University.